Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pepijn Vemer

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Human Vaccines & Immunotherapeutics|November 27, 2014
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch childrenPepijn Vemer, Maarten J Postma
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|March 19, 2015
Higher Adherence During Reimbursement of Pharmacological Smoking Cessation TreatmentsJob F M van Boven, Pepijn Vemer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countriesPepijn Vemer, Maureen P M H Rutten-van Mölken
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 1, 2010
Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factorPepijn Vemer, Maureen P M H Rutten-van Mölken
Pharmacoeconomics|August 28, 2013
The road not taken: transferability issues in multinational trialsPepijn Vemer, Maureen P M H Rutten-van Mölken
Plos One|August 30, 2016
Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims DataYunyu Huang, Pepijn Vemer, Jingjing Zhu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2017
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the NetherlandsSimon van der Pol, Fabian Degener, Maarten J Postma, et al.
International Journal of Nursing Studies|June 23, 2020
The risk of overestimating cost savings from hospital-at-home schemes: A literature reviewLucas M A Goossens, Pepijn Vemer, Maureen P M H Rutten-van Mölken
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 14, 2014
Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertaintyPepijn Vemer, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
Pharmacoeconomics|May 1, 2016
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerPieter T de Boer, Geert W J Frederix, Talitha L Feenstra, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|November 27, 2014
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch childrenPepijn Vemer, Maarten J Postma
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|March 19, 2015
Higher Adherence During Reimbursement of Pharmacological Smoking Cessation TreatmentsJob F M van Boven, Pepijn Vemer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countriesPepijn Vemer, Maureen P M H Rutten-van Mölken
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 1, 2010
Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factorPepijn Vemer, Maureen P M H Rutten-van Mölken
Pharmacoeconomics|August 28, 2013
The road not taken: transferability issues in multinational trialsPepijn Vemer, Maureen P M H Rutten-van Mölken
Plos One|August 30, 2016
Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims DataYunyu Huang, Pepijn Vemer, Jingjing Zhu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 16, 2017
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the NetherlandsSimon van der Pol, Fabian Degener, Maarten J Postma, et al.
International Journal of Nursing Studies|June 23, 2020
The risk of overestimating cost savings from hospital-at-home schemes: A literature reviewLucas M A Goossens, Pepijn Vemer, Maureen P M H Rutten-van Mölken
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 14, 2014
Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertaintyPepijn Vemer, Lucas M A Goossens, Maureen P M H Rutten-van Mölken
Pharmacoeconomics|May 1, 2016
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerPieter T de Boer, Geert W J Frederix, Talitha L Feenstra, et al.
Pageof 3